Company / Return on Equity (ROE)
Pasithea Therapeutics Corp. Return on Equity (ROE) History
FY2021-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-4.2%
FY2022
5-year range
-17.0% / -4.2%
FY2021-FY2022
Trend
+75.1%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Pasithea Therapeutics Corp. reports negative total equity of -4.2% in FY2022. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-4.2% in FY2022.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, return on equity (roe) increased 75.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2022 | -4.2% | +75.1% |
| FY2021 | -17.0% | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026